drugset / Trial / NCT00817778

Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

NCT00817778

Phase 2 Completed 27 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Metformin

Timeline

Start
2009-01
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1656 Small molecule Oral